Humedix Co Ltd Total Assets
Humedix Co Ltd total assets. Based on the latest financial reports, Humedix Co Ltd (200670) holds total assets worth ₩334.64 Billion KRW (≈ $226.78 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Humedix Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Humedix Co Ltd (2015–2025)
Total assets of Humedix Co Ltd from 2015 to 2025. This chart illustrates how Humedix Co Ltd's total assets have evolved over time, based on quarterly financial data. See latest Humedix Co Ltd stock price today for real-time trading data and today's change.
Humedix Co Ltd - Asset Composition Analysis
Humedix Co Ltd Total Assets Breakdown (December 2025)
Humedix Co Ltd total assets breakdown as of December 2025. Humedix Co Ltd's total assets of ₩334.64 Billion consist of 55.4% current assets and 44.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 12.3% |
| Accounts Receivable | ₩29.27 Billion | 9.0% |
| Inventory | ₩21.39 Billion | 6.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩2.35 Billion | 0.7% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Humedix Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 200670 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humedix Co Ltd's current assets represent 55.4% of total assets in 2025, a decrease from 71.1% in 2015.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2025, down from 58.4% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 9.0% of total assets.
Humedix Co Ltd Competitors by Total Assets
Key competitors of Humedix Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Galderma Group N
SW:GALD
|
Switzerland | CHF12.88 Billion |
|
Enzymatica publ AB
ST:ENZY
|
Sweden | Skr149.24 Million |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥13.98 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
Humedix Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.30 | 9.48 | 4.18 |
| Quick Ratio | 6.11 | 8.04 | 3.45 |
| Cash Ratio | 0.00 | 0.00 | 0.65 |
| Working Capital | ₩151.63 Billion | ₩164.12 Billion | ₩80.61 Billion |
Humedix Co Ltd - Advanced Valuation Insights
This section examines the relationship between Humedix Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 29.6% |
| Total Assets | ₩323.64 Billion |
| Market Capitalization | $170.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Humedix Co Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Humedix Co Ltd's assets grew by 29.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Humedix Co Ltd (2015–2025)
The table below shows the annual total assets of Humedix Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩323.64 Billion ≈ $219.33 Million |
+29.58% |
| 2024-12-31 | ₩249.75 Billion ≈ $169.25 Million |
+13.54% |
| 2023-12-31 | ₩219.98 Billion ≈ $149.08 Million |
-3.15% |
| 2022-12-31 | ₩227.14 Billion ≈ $153.93 Million |
+5.22% |
| 2021-12-31 | ₩215.86 Billion ≈ $146.29 Million |
+22.90% |
| 2020-12-31 | ₩175.65 Billion ≈ $119.03 Million |
+26.89% |
| 2019-12-31 | ₩138.42 Billion ≈ $93.81 Million |
+7.91% |
| 2018-12-31 | ₩128.28 Billion ≈ $86.93 Million |
-1.13% |
| 2017-12-31 | ₩129.74 Billion ≈ $87.92 Million |
-1.08% |
| 2016-12-31 | ₩131.16 Billion ≈ $88.88 Million |
+13.17% |
| 2015-12-31 | ₩115.90 Billion ≈ $78.54 Million |
-- |
About Humedix Co Ltd
Humedix Co., Ltd. engages in the manufacture and sale of various pharmaceutical products in South Korea. The company offers prescription medicines, active pharmaceutical ingredients, medical devices, cosmetics, and health functional food products. It is also involved in the manufacture and distribution of anticancer drugs. The company was formerly known as HVLS Co., Ltd. and changed its name to H… Read more